MAGL inhibition does not alter consumption or locomotion. a–c, JZL (8 mg/kg, i.p.) treatment across two consecutive sessions (S1, S2) did not alter free-access sucrose consumption (two-way RM ANOVA; treatment: F_(1,34) = 0.52, p = 0.475; a) or open-field locomotion measured by distance traveled (two-way RM ANOVA; treatment: F_(1,34) = 1.42, p = 0.249; b) and movement velocity (two-way RM ANOVA; treatment: F_(1,34) = 1.42, p = 0.249; c). Post hoc comparison following significant main effect of time, S1 vs S2, ***p < 0.001.